medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2026, Number 1

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2026; 24 (1)

Excimer laser: an underestimated tool in the therapeutic arsenal for alopecia areata

Gómez FM, Lazcano PBR, Alvarado CRI

Language: Spanish
References: 14
Page: 124-129
PDF size: 373.53 Kb.


ABSTRACT

BACKGROUND: Alopecia areata (AA) is a non-scarring autoimmune disorder characterized by sudden hair loss and significant impairment of quality of life. Despite multiple available therapies, many patients experience incomplete responses or frequent relapses, highlighting the need for effective and safe alternatives. The 308-nm excimer laser has emerged as a promising non-pharmacological option.
METHODS: We report two pediatric cases of refractory alopecia areata treated with weekly 308-nm excimer laser therapy, with progressive dose escalation according to clinical tolerance.
RESULTS: Both patients achieved clinically significant hair regrowth with 12 to 17 weekly sessions up to a maximum of 300 mJ/cm².
CONCLUSIONS: The 308-nm excimer laser is a safe, effective, and accessible therapeutic alternative for pediatric patients with refractory alopecia areata, offering a valuable option to reduce reliance on systemic therapies.


REFERENCES

  1. Lee JH, Eun SH, Kim SH, Ju HJ, Kim GM, Bae JM. Excimerlaser/light treatment of alopecia areata: A systematic reviewand meta-analyses. Photodermatology Photoimmunology& Photomedicine [Internet]. Wiley; 2020 Aug 3 [cited 2025Nov];36(6):460. Disponible en: https://doi.org/10.1111/phpp.12596

  2. Bujan M. Alopecia areata. Archivos Argentinos de Pediatria[Internet]. 2013 Sep 6 [cited 2025 Feb];111(5):455. Disponibleen: https://doi.org/10.5546/aap.2013.455

  3. Sanga ZN. Comparative study of efficacy of excimer lighttherapy vs. intralesional triamcinolone vs. topical 5% minoxidilfor alopecia areata: an observational study. Dermatology Review[Internet]. 2015 Jan 1 [cited 2025 Sep];3:206. Disponible en:https://doi.org/10.5114/dr.2015.51921

  4. Hamzawi NKA, Baaj MSA. Overview of the Role of 308Monochromatic Excimer Phototherapy for the Treatment ofAlopecia Areata. In: IntechOpen eBooks [Internet]. IntechOpen;2022 [cited 2025 Sep]. Disponible en: https://doi.org/10.5772/intechopen.108531

  5. Velásquez-Lopera MM, Mantilla NH, Jansen AM, Londoño Á,Luna PC, Rico-Restrepo M, et al. Alopecia Areata in LatinAmerica: Where are we and where are we Going? Dermatologyand Therapy [Internet]. Adis, Springer Healthcare; 2022Dec 17 [cited 2025 Oct];13(1):95. Disponible en: https://doi.org/10.1007/s13555-022-00845-4

  6. Rakowska A, Rudnicka L, Olszewska M, Bergler-Czop B,Czuwara J, Brzez´in´ska-Wcisło L, et al. Alopecia areata.Diagnostic and therapeutic recommendations of the PolishSociety of Dermatology. Part 2: Treatment. DermatologyReview [Internet]. 2023 Jan 1 [cited 2025 Oct];110(2):101.Disponible en: https://doi.org/10.5114/dr.2023.127705

  7. Serbina I, Кhobzei K, Лядова Т, Litus OI, Vozianova S,Andrashko Y, et al. Clinical guidelines of ukrainian hairresearch society. diagnosis and treatment of alopecia areata.Actual problems of modern medicine [Internet]. 2023 Nov28 [cited 2025 Oct];(12):45. Disponible en: https://doi.org/10.26565/2617-409x-2023-12-06

  8. Jean-Pierre P, Pulumati A, Kasheri E, Hirsch M, Nouri K. Lasersin the management of alopecia: a review of establishedtherapies and advances in treatment. Lasers in MedicalScience [Internet]. Springer Science+Business Media; 2024Apr 17 [cited 2026 Jan];39(1):102. Disponible en: https://doi.org/10.1007/s10103-024-04054-7

  9. Egeberg A, Linsell L, Johansson E, Durand F, Yu G, Vañó-Galván S. Treatments for Moderate-to-Severe Alopecia Areata:A Systematic Narrative Review. Dermatology and Therapy[Internet]. Adis, Springer Healthcare; 2023 Oct 13 [cited 2025Aug];13(12):2951. Disponible en: https://doi.org/10.1007/s13555-023-01044-5

  10. Phillipps J. Adjuvant Scalp Rolling for Patients With RefractoryAlopecia Areata [Internet]. Vol. 112, Cutis. Frontline MedicalCommunications; 2023 [cited 2025 Oct]. Disponible en: https://doi.org/10.12788/cutis.0829

  11. Liu M, Gao Y, Yuan Y, Yang K, Shen C, Wang J, et al. JanusKinase Inhibitors for Alopecia Areata. JAMA Network Open[Internet]. American Medical Association; 2023 Jun 27[cited 2025 Oct];6(6). Disponible en: https://doi.org/10.1001/jamanetworkopen.2023.20351

  12. Rudnicka L, Trzeciak M, Alpsoy E, Arenberger P, Alper S,Benáková N, et al. Disease burden, clinical management andunmet treatment need of patients with moderate to severealopecia areata: consensus statements, insights, and practicesfrom CERTAAE (Central/Eastern EU, Russia, Türkiye AA experts)Delphi panel. Frontiers in Medicine [Internet]. 2024 Apr 22[cited 2025 Oct];11. Disponible en: https://doi.org/10.3389/fmed.2024.1353354

  13. Patel P. Evaluating the Cost Burden of Alopecia AreataTreatment: A Comprehensive Review for Dermatologists. Cutis[Internet]. Frontline Medical Communications; 2024 Apr 1[cited 2025 Oct];113(4). Disponible en: https://doi.org/10.12788/cutis.0994

  14. Obeime I, Larrondo J, McMichael A. Alopecia Areata in Skin ofColor Patients: New Considerations Sparked by the Approval ofBaricitinib. Cutis [Internet]. 2023 Jan 1 [cited 2025 Oct];111(1).Disponible en: https://doi.org/10.12788/cutis.0685




2020     |     www.medigraphic.com